In this study, the incidence of BRAF mutations was significantly higher in patients with MSI-H (45%) than with MSS tumours (1.6% P=<0.001), in agreement with the published evidence (Rajagopalan et al, 2002; Oliveira et al, 2003; Wang et al, 2003). Here, BRAF is linked to neoplasm.